Retatrutide
Also called reta, LY3437943, LY-3437943.
Retatrutide is still investigational, with no FDA-approved product. This page cites 1 source, and the strongest evidence comes from human trials.
- Status
- Investigational
- Form
- Injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 1
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
In TRIUMPH-1, retatrutide reduced body weight more than placebo over 80 weeks in adults with obesity without diabetes.
Limits: This randomized, double-blind phase 3 trial enrolled 2,339 adults. Gastrointestinal adverse events were most common. The trial does not establish lifelong safety, results after stopping, or the quality of products sold outside the study.
Regulatory status
United States
Investigational and not FDA-approved for any indication as of November 6, 2026. FDA identifies retatrutide as not a component of an approved drug.